Enveric Biosciences (ENVB) on Thursday shared mechanistic data that's getting to the heart of what makes psychedelic-inspired drugs tick—or more precisely, what makes them therapeutic without making you hallucinate.
The company's lead candidate, EB-003, activates both Gq and β-arrestin–mediated signaling downstream of the 5-HT₂A receptor. If that sounds technical, here's why it matters: these are two distinct pathways in your brain, and emerging evidence suggests they might do different things. One pathway could deliver the therapeutic goods, while another might trigger the hallucinogenic experience that makes clinical use complicated.
Enveric is developing EB-003 as a non-hallucinogenic neuroplastogen, designed to support streamlined treatment approaches that could potentially include at-home administration. That's a big deal in psychiatry, where promising psychedelic compounds often require hours of supervised sessions in clinical settings.
Building the Science Foundation
The new data were generated using proprietary bioluminescence resonance energy transfer (BRET) assays. Enveric built these assays in-house because commercial options capable of reliably measuring pathway-specific 5-HT₂A signaling simply weren't available. The results demonstrate biologically relevant engagement of both Gq and β-arrestin pathways, with EB-003 showing a modest preference toward β-arrestin over Gq signaling relative to serotonin, the receptor's native ligand.
Multiple independent, peer-reviewed studies have previously demonstrated that selective activation of the 5-HT₂A receptor—by either Gq-biased or β-arrestin–biased agonists—can independently produce antidepressant and anxiolytic-like effects in preclinical models. The company is now exploring the mechanistic significance of EB-003's apparent bias.
New Academic Research Adds Clarity
A recently published study in Nature using BRET assays and complementary techniques provides additional mechanistic insight into signaling downstream of 5-HT₂A. The research reports that Gi signaling downstream of 5-HT₂A was required for hallucinogenic effects in experimental models, while Gq signaling mediated antidepressant and anxiolytic-like benefits in preclinical systems. These findings suggest that therapeutic benefit and hallucinations may arise from distinct intracellular pathways.
"Growing mechanistic clarity around 5-HT₂A signaling strengthens confidence in the scientific foundation of our platform," said Joseph Tucker, CEO of Enveric Biosciences.
Tucker added that Enveric is planning additional BRET testing of EB-003, including the Gi pathway, to further characterize its unique signaling mechanisms.
Tucker told MarketDash that "mechanistic uncertainty is a major reason CNS drugs fail. Understanding the signaling biology before clinical trials begin helps reduce that risk."
Regarding hallucinations, he explained: "We haven't tested EB-003 in humans yet, so we can't make clinical claims, although our preclinical work using a proxy for hallucinations is encouraging. We do have more work to do on the newly singled out pathways, to see if or how EB-003 is engaging with them."
On the potential for at-home use, Tucker was measured: "Our goal is a therapy compatible with standard prescribing rather than monitored sessions. Whether it can be used at home will depend entirely on clinical safety and regulatory review."
Looking ahead, Tucker said the company is "advancing IND-enabling studies while expanding pathway characterization so that we enter clinical testing with a well-understood mechanism."
Enveric continues to advance EB-003 through IND-enabling studies as it works toward clinical testing.
ENVB Price Action: Enveric shares were up 9.82% at $2.46 in premarket trading on Thursday, according to market data.
